StockNews.com upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN - Free Report) from a buy rating to a strong-buy rating in a report issued on Tuesday morning.
BMRN has been the subject of a number of other research reports. Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. Royal Bank of Canada restated a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Piper Sandler increased their target price on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a research note on Thursday, February 20th. UBS Group boosted their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Finally, Oppenheimer upgraded BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price objective on the stock in a research report on Monday, February 24th. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.
Check Out Our Latest Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
Shares of BMRN stock traded down $0.36 on Tuesday, reaching $71.24. The stock had a trading volume of 894,223 shares, compared to its average volume of 1,773,723. BioMarin Pharmaceutical has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $13.59 billion, a price-to-earnings ratio of 32.19, a P/E/G ratio of 0.61 and a beta of 0.33. The firm's 50-day moving average is $66.50 and its two-hundred day moving average is $68.42.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, research analysts expect that BioMarin Pharmaceutical will post 3.15 EPS for the current fiscal year.
Insider Buying and Selling at BioMarin Pharmaceutical
In related news, CAO Erin Burkhart sold 1,295 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the transaction, the chief accounting officer now owns 16,955 shares in the company, valued at $1,212,621.60. This trade represents a 7.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.85% of the company's stock.
Institutional Trading of BioMarin Pharmaceutical
A number of institutional investors and hedge funds have recently bought and sold shares of BMRN. California State Teachers Retirement System grew its position in shares of BioMarin Pharmaceutical by 2.7% in the 4th quarter. California State Teachers Retirement System now owns 273,761 shares of the biotechnology company's stock valued at $17,994,000 after buying an additional 7,094 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in BioMarin Pharmaceutical by 295.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,201 shares of the biotechnology company's stock valued at $1,525,000 after purchasing an additional 17,340 shares during the period. Lansforsakringar Fondforvaltning AB publ acquired a new stake in BioMarin Pharmaceutical during the 4th quarter valued at approximately $4,367,000. PKO Investment Management Joint Stock Co acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $789,000. Finally, Siemens Fonds Invest GmbH bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at $821,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.
About BioMarin Pharmaceutical
(
Get Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
